Naga Chalasani

发表

Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis

Thomas F Imperiale, N. Chalasani, T. Imperiale, 2003, American Journal of Gastroenterology.

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Michael Charlton, K. Cusi, N. Chalasani, 2018, Hepatology.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

Mariza de Andrade, Andre Franke, Wolfgang Lieb, 2016, Nature Genetics.

Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies.

Joseph Bockhorst, Scott Vanderbeck, Joseph Bockhorst, 2015, Human pathology.

Annals of the New York Academy of Sciences Nonalcoholic Fatty Liver Disease: an Emerging Threat to Obese and Diabetic Individuals

N. Chalasani, H. Masuoka, Naga Chalasani, 2022 .

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Michael Charlton, K. Cusi, N. Chalasani, 2012, American Journal of Gastroenterology.

Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.

James Nguyen, Raj Vuppalanchi, N. Chalasani, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes

Jiezhun Gu, Jiezhun Gu, N. Chalasani, 2017, Journal of clinical gastroenterology.

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

William M. Lee, Huiman X. Barnhart, Robert J. Fontana, 2015, Gastroenterology.

Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals

Chandan Saha, E. Bjornsson, N. Chalasani, 2008, Hepatology.

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Michael Charlton, K. Cusi, N. Chalasani, 2012, Gastroenterology.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

B. Neuschwander‐Tetri, N. Chalasani, M. V. Van Natta, 2010, Hepatology.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

Raj Vuppalanchi, N. Chalasani, R. Vuppalanchi, 2009, Hepatology.

Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

Tariq Hameed, Raj Vuppalanchi, O. Cummings, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Joe Kesterson, N. Chalasani, H. Aljadhey, 2004, Gastroenterology.

Predictors of inadequate bowel preparation for colonoscopy

N. Chalasani, R. Ness, Naga Chalasani, 2001, American Journal of Gastroenterology.

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Jiri Aubrecht, John-Michael Sauer, Simon Kirby, 2018, Hepatology.

Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.

Raj Vuppalanchi, O. Cummings, N. Chalasani, 2011, Journal of hepatology.